{"nctId":"NCT02769481","briefTitle":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","startDateStruct":{"date":"2016-08-15","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":426,"armGroups":[{"label":"Bexagliflozin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bexagliflozin","Drug: Placebo for Glimepiride"]},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo for Bexagliflozin","Drug: Glimepiride"]}],"interventions":[{"name":"Bexagliflozin","otherNames":["EGT0001442"]},{"name":"Placebo for Bexagliflozin","otherNames":[]},{"name":"Glimepiride","otherNames":[]},{"name":"Placebo for Glimepiride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of T2DM\n* Currently taking metformin or taking metformin and one additional oral medication for diabetes\n* Body Mass Index (BMI) ≤ 45 kg/m2\n* Stable dose of blood pressure or cholesterol medications (if applicable) for at least 30 days\n\nExclusion Criteria:\n\n* Hypersensitivity or other contraindication to the safe use of sulfonylurea or glimepiride\n* Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young\n* Current use of injected therapy for treatment of diabetes (insulin or GLP-1 receptor agonist therapy) or thiazolidinedione class drugs\n* History of genitourinary tract infections\n* Evidence of abnormal liver function\n* Myocardial infarction, stroke or hospitalization for heart failure within 3 months of screening\n* Prior kidney transplant or evidence of kidney problems\n* Pregnant or nursing","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c at Week 60","description":"The primary objective is to demonstrate that bexagliflozin is non-inferior to glimepiride by evaluating the treatment effect on HbA1c reduction at week 60 in subjects whose T2DM is inadequately controlled by metformin. The least square mean (LSM) change from baseline to Week 60 was analyzed using a mixed model repeated measures (MMRM) analysis of covariance model (ANCOVA).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.70","spread":"0.058"},{"groupId":"OG001","value":"-0.66","spread":"0.058"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 60 for Subjects With Baseline BMI ≥ 25 kg/m2","description":"Least squares (LS) mean treatment difference between the bexagliflozin group and placebo group in the change of body weight in subjects with baseline BMI ≥ 25 kg/m2 at week 60 is analyzed using ANCOVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.71","spread":"0.285"},{"groupId":"OG001","value":"0.59","spread":"0.284"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Systolic Blood Pressure (SBP) at Week 60 for Subjects With Baseline SBP ≥ 140 mmHg","description":"Least squares (LS) mean treatment difference between the bexagliflozin group and placebo group in the change of SBP in subjects with baseline SBP ≥ 140 mmHg at week 60 is analyzed using ANCOVA.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.48","spread":"1.404"},{"groupId":"OG001","value":"-6.95","spread":"1.460"}]}]}]},{"type":"SECONDARY","title":"Difference in Proportion of Subjects With ≥ 1 Severe or Documented Symptomatic Hypoglycemia Events Over 96 Weeks","description":"The difference in proportion of subjects with ≥ 1 severe or documented symptomatic hypoglycemia events in the bexagliflozin group compared with glimepiride group over 96 weeks is analyzed using a logistic regression model. The full model included region, baseline HbA1c value, background treatment status (metformin or metformin + OHA), eGFR at baseline ≥ 90 or \\< 90 mL min 1 per 1.73 m2), treatment as a fixed effect covariate.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":null},{"groupId":"OG001","value":"0.15","spread":null}]}]}]},{"type":"SECONDARY","title":"Superiority of Bexagliflozin Over Glimepiride in HbA1c Reduction at Week 60.","description":"Superiority of bexagliflozin over glimepiride in HbA1c reduction from baseline to week 60 will be declared if the upper bound of 95% CI is less than 0.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.70","spread":"0.058"},{"groupId":"OG001","value":"-0.66","spread":"0.058"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":213},"commonTop":["Hypoglycemia","Nasopharyngitis","Urinary Tract Infection","Bronchitis","Back pain"]}}}